Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Apr 30;20(6):353. doi: 10.1038/s41577-020-0335-0

Impaired interferon signature in severe COVID-19

Conor Gruber 1,
PMCID: PMC7192056  PMID: 32355328

In this preprint, Hadjadj et al. analyse the late-stage immune responses in 50 patients with COVID-19 spanning a range of disease severity but controlled for age, duration from symptom onset and comorbidities. Compared with mild or moderate cases, severe and critically ill patients have a profoundly impaired type I interferon response, despite comparable viral loads as measured by nasal swab. In addition, clinical severity correlated with increased IL-6, TNF and chemokine signatures. These findings suggest that type I interferon may hold promise for prognostic and therapeutic strategies. Further studies of these cytokines earlier in disease and with more precise quantification of viral load in the respiratory tract will be crucial to validate the result.

Competing interests

The author declares no competing interests.

References

Original article

  1. Hadjadj J, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv. 2020 doi: 10.1101/2020.04.19.20068015. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES